Menu
Not yet recruiting NCT07608445

Physiatry-Led Cancer Prehabilitation During Neoadjuvant Systemic Therapy to Improve Function in Stage III-IVA Gynecologic Cancer Patients

No phase Interventional Malignant Female Reproductive System Neoplasm

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Educational Intervention, Goal Setting, Interview, Referral.
Who it may be relevant to
Registry conditions: Malignant Female Reproductive System Neoplasm. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Physiatry-Led Prehabilitation During Neoadjuvant Systemic Treatment Before Surgery for Advanced Gynecological Cancer: A Pilot Feasibility Study

Overview

This clinical trial studies whether physiatry-led cancer prehabilitation can be used during systemic treatment before surgery (neoadjuvant systemic treatment \[NST\]) to improve function in stage III-IVA gynecologic cancer patients. Treatment of gynecologic cancers presents significant challenges to physical and mental health and patients often experience many challenges following treatment including sleep disturbance, extreme tiredness, sexual dysfunction, and bowel and urinary problems. Patients who have low functioning prior to surgery often have worse outcomes following surgery; however, services to support functional shortages often start after surgery. Physiatry-led cancer prehabilitation is a strategy aimed at reducing post-treatment functional challenges by improving physical and mental function before treatment. It involves physiatry, which is a medical specialty focused on function. Physiatry involvement in prehabilitation allows for the evaluation and management of co-existing conditions, medical supervision, and the coordination of complex plans involving multiple teams. Using physiatry-led cancer prehabilitation during NST may be an effective way to improve function in stage III-IVA gynecologic cancer patients.

Detailed description

PRIMARY OBJECTIVES:

I. Determine feasibility based on adherence (\> 70%) across the key components-exercise (aerobic and resistance), nutrition, and mind/spirit practice-in \> 70% of enrolled patients for the 28-day period immediately prior to surgery.

II. Evaluate feasibility via enrollment rate \> 50% of eligible patients.

SECONDARY OBJECTIVES:

I. Evaluate physical measures: Six Minute Walk Test, Duke Activity Status Index, 30-second Sit to Stand, Short Physical Performance Battery, Patient Reported Outcomes Measurement Information System (PROMIS) Cancer Function Brief Three Domains (3D) Profile, and body composition.

II. Assess exercise behavior measures: Godin-Shephard Leisure-Time Physical Activity Questionnaire, self-reported exercise activity and future intent, Self-Efficacy for Home Exercise Programs.

III. Evaluate malnutrition risk with Malnutrition Screening Tool. IV. Assess psychological and spiritual distress with relevant measures within the Edmonton Symptom Assessment Scale- Financial and Spiritual Distress (ESAS-FS) and European Quality of Life 5 Dimensions (EQ-5D-5L).

V. Evaluate symptom burden with ESAS-FS and health-related quality of life with EQ-5D-5L.

EXPLORATORY OBJECTIVES:

I. Evaluate the impact of the tailored prehabilitation program on disease outcomes as measured by Relative Dose Intensity, pathologic complete response, Response Evaluation Criteria in Solid Tumors, and cancer antigen 125 (CA-125).

II. Evaluate the impact of the tailored prehabilitation program on cancer treatment timing by examining time from diagnosis to surgery, time from last chemotherapy cycle to surgery, time from surgery to adjuvant treatment, hospitalizations and length of stay.

III. Evaluate the impact of the tailored prehabilitation program on cancer treatment complications, measured by the incidence of chemotherapy-induced peripheral neuropathy (using Common Terminology Criteria for Adverse Events \[CTCAE\] 5.0) and 30-day readmission rate.

IV. Identify future program improvements via a participant feedback survey and/or interview, clinician feedback survey and/or interview, reasons for non-participation, challenges to intervention adherence, and days to consult completion.

V. Document the utilization of multidisciplinary specialty services.

OUTLINE:

Patients attend a cancer physiatry consultation over 1 hour and receive an introduction to the home-based program, a starter prescription, and written prehabilitation education materials before the start of cycle 2 of NST. Patients then follow the provided starter prescription and attempt to meet aerobic exercise, resistance exercise, nutrition, and psychospiritual goals at home during and while off NST in the absence of unacceptable toxicity. Patients also attend additional cancer physiatry consultation follow-ups at 28 days and at 28 days after surgery. Additionally, patients receive resistance bands, sources for nutritional guidance, and practical tips and resources on study and may also receive tailored multidisciplinary referrals as needed.

Interventions

  • Other Educational Intervention
    Receive written prehabilitation education materials
  • Other Goal Setting
    Follow and meet prehabilitation goals
  • Other Interview
    Ancillary studies
  • Other Referral
    Receive tailored multidisciplinary referrals
  • Procedure Rehabilitation
    Attend cancer physiatry consultation
  • Other Supportive Care
    Receive resistance bands, nutritional guidance sources, and tips and resources
  • Other Survey Administration
    Ancillary studies
  • Procedure Tailored Intervention
    Receive starter prescription

Primary outcome measures

  • Participant completion and adherence to the prescribed training program (Feasibility) [Time frame: Up to 28 days immediately prior to surgery]
Secondary outcome measures (12)
  • Enrollment rate (Feasibility) [Time frame: Up to 1 year]
  • Change in physical measures - Six Minute Walk Test (6MWT) [Time frame: From Baseline up to 21-35 days post-surgery]
  • Change in physical measures - Duke Activity Status Index (DASI) [Time frame: From Baseline up to 21-35 days post-surgery]
  • Change in physical measures - 30-second Sit to Stand (30STS) [Time frame: From Baseline up to 21-35 days post-surgery]
  • Change in physical measures - Short Physical Performance Battery (SPPB) [Time frame: From Baseline up to 21-35 days post-surgery]
  • Change in physical measures - Reported Outcomes Measurement Information System (PROMS) Cancer Function Brief 3D Profile [Time frame: From Baseline up to 21-35 days post-surgery]
  • Change in physical measures - Body composition [Time frame: From Baseline up to 21-35 days post-surgery]
  • Change in exercise behavior measures - Godin-Shephard Leisure-Time Physical Activity Questionnaire [Time frame: From Baseline to 21-35 days post-surgery]
  • Change in exercise behavior measures - Self-reported exercise activity [Time frame: From Baseline to 21-35 days post-surgery]
  • Change in exercise behavior measures - Self-Efficacy for Home Exercise Programs (SEHEPS) [Time frame: From Baseline to 21-35 days post-surgery]
  • Change in malnutrition risk [Time frame: Baseline to 21-35 days post-surgery]
  • Change in psychological and spiritual distress [Time frame: Baseline to 21-35 days post-surgery]

Eligibility criteria

Inclusion criteria

  • PATIENT: Documented informed consent of the participant
  • PATIENT: Willingness to comply with a physiatry consultation, start a tailored training program, and follow-up assessments
  • PATIENT: Age: ≥ 18 years
  • PATIENT: Able to read and write in English
  • PATIENT: A diagnosis of stage III-IVA gynecologic cancer planned for NST
  • PATIENT: Plan to start NST at City of Hope Orange County
  • HEALTHCARE TEAM: Documented informed consent of the participant
  • HEALTHCARE TEAM: Willingness to complete the Healthcare Worker Survey
  • HEALTHCARE TEAM: ≥ 18 years old
  • HEALTHCARE TEAM: Physicians, advanced practice providers, nurses, medical assistants, rehabilitation therapists, social workers, dietitians, mental health professionals, and other clinical staff who interact with study participants in the course of routine care

Exclusion criteria

  • PATIENT: Current or planned cancer treatment for a second cancer
  • PATIENT: Clinically significant uncontrolled illness limiting participation with the research intervention and assessments
  • PATIENT: Stage IVB cancer with distant metastases
  • PATIENT: Other active malignancy
  • PATIENT: Pregnant or breastfeeding
  • PATIENT: Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
  • PATIENT: Meeting or exceeding exercise guidelines over the last one month based on the responses from the Godin-Shephard Leisure Time Physical Activity Questionnaire (GSLTPAQ)
  • PATIENT: Started second cycle before the physiatry consult
  • PATIENT: Inability to independently follow instructions for study assessments for any reason such as mental incapacitation or significant emotional or psychological disorder that, in the opinion of the investigators, precludes study entry. (These patients may not be able to cooperate with the prehabilitation interventions or with the data collection process.)
  • PATIENT: Unable to independently answer questionnaires in English
  • HEALTHCARE TEAM: Healthcare workers who do not interact with study participants and therefore cannot provide relevant feedback

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Supportive care

Study locations

United States · 2 centers
  • City of Hope Medical Center — Duarte
  • City of Hope at Irvine Lennar — Irvine

Identifiers

NCT: NCT07608445 · 24765 · P30CA033572 · NCI-2026-03209 · 24765

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗